Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), Or Post-Essential Thrombocythemia MF (Post-ET MF)

Trial Profile

A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), Or Post-Essential Thrombocythemia MF (Post-ET MF)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2019

At a glance

  • Drugs PRM 151 (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Therapeutic Use
  • Sponsors Promedior
  • Most Recent Events

    • 17 Jun 2019 Results published in the Promedior Media Release.
    • 17 Jun 2019 According to an Promedior Media release, positive data from this study were presented in an oral presentation at the 24th European Hematology Association (EHA) Annual Congress.
    • 04 Dec 2018 Results (n=18) open-label extension study of PRM-151 assessing safety and efficacy of the drug, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top